FIG. 1A


IgG1 control, 4 mg/kg
IgG1-MMAE control, 4 mg/kg
cisplatin, 4 mg/kg
tisotumab vedotin, 2 mg/kg
tisotumab vedotin, 2 mg/kg and cisplatin, 4 mg/kg
cisplatin treatment
antibody/ADC treatment
Tumor size + SEM (mm³)
2000
1000
0
0
10
20
30
days after first treatment

FIG. 1B


IgG1 control, 4 mg/kg
IgG1-MMAE control, 4 mg/kg
tisotumab vedotin, 4 mg/kg
cisplatin, 4 mg/kg
tisotuman vedotin, 4 mg/kg and cisplatin, 4 mg/kg
cisplatin treatment
antibody/ADC treatment
Tumor size + SEM (mm³)
2000
1000
0
0
10
20
30
days after first treatment

FIG. 1C


Tumor size (mm3)
3000
2000
1000
0
Group 01, IgG1control, 4 mg/kg
Group 02, IgG1-MMAE control, 4 mg/kg
Group 03, tisotumab vedotin, 4 mg/kg
Group 04, tisotumab vedotin, 2 mg/kg
Group 05, tisotumab vedotin, 1 mg/kg
Group 06, tisotumab vedotin, 0.5 mg/kg
Group 07, cisplatin, 4 mg/kg, TV, 4 mg/kg
Group 08, cisplatin, 4 mg/kg, TV, 2 mg/kg
Group 09, cisplatin, 4 mg/kg, TV, 1 mg/kg
Group 10, cisplatin, 4 mg/kg, TV, 0.5 mg/kg
Group 11, cisplatin, 4 mg/kg, TV

FIG. 1D


Percent tumor free (<1000mm3)
100
50
0
0
20
40
60
80
Days after randomization
IgG1-MMAE control, 4 mg/kg
cisplatin, 4 mg/kg
tisotumab vedotin, 4 mg/kg
tisotumab vedotin, 4 mg/kg and cisplatin, 4 mg/kg

FIG. 1E


Percent tumor free (<1000mm3)
100
50
0
0
20
40
60
80
Days after randomization
IgG1-MMAE control, 4 mg/kg
cisplatin, 4 mg/kg
tisotumab vedotin, 2 mg/kg
tisotumab vedotin, 2 mg/kg and cisplatin, 4 mg/kg

FIG. 2A


2000
1500
1000
500
0
Tumorsize (mm3)
0
20
40
60
80
Days after treatment
IgG1-MMAE
cisplatin
tisotumab vedotin
tisotumab vedotin and cisplatin
ADC treatment
cisplatin treatment

FIG. 2B


Tumorsize (mm³)
2000
1500
1000
500
0
IgG1-MMAE
isotumab vedotin
cisplatin
isotumab vedotin/cisplatin


Tumorsize (mm³)
3000
2000
1000
0
isotumab vedolin
isotumab vedolin/cisplatin

FIG. 2C

FIG. 2D


Percent tumor free (<500mm3)
100
50
0
0
14
28
42
56
70
84
98
Days after treatment
IgG1-MMAE
cisplatin
tisotumab vedotin
tisotumab vedotin/cisplatin

FIG. 3A


A
1500
1000
500
0
Tumor volume (mm3)
0
10
20
30
40
50
Days after first treatment
IgG1 control, 2 mg/kg
IgG1-MMAE control, 2 mg/kg
Tisotumab vedotin, 2 mg/kg
carboplatin, 40mg/kg
carboplatin, 80mg/kg
Tisotumab vedotin, 2 mg/kg + carboplatin, 40 mg/kg
Tisotumab vedotin, 2 mg/kg + carboplatin, 80 mg/kg
Treatment

FIG. 3B


B
Tumor volume (mm3)
2000
1500
1000
500
0
IgG1 control, 2 mg/kg
IgG1-MMAE control, 2 mg/kg
Tisotumab vedotin, 2 mg/kg
Carboplatin, 40 mg/kg
Carboplatin, 80 mg/kg
Tisotumab vedotin, 2 mg/kg + carboplatin, 40mg/kg
Tisotumab vedotin, 2 mg/kg + carboplatin, 80 mg/kg

FIG. 3C

C


% mice with tumor volume < 750 mm3
100
50
0
0
20
40
60
Days after initial treatment
IgG1 control, 2 mg/kg
IgG1-MMAE control, 2 mg/kg
Tisotumab vedotin, 2 mg/kg
Carboplatin, 40 mg/kg
Carboplatin, 80 mg/kg
Tisotumab vedotin, 2 mg/kg + carboplatin, 40 mg/kg
Tisotumab vedotin, 2 mg/kg + carboplatin, 80 mg/kg

FIG. 4A


Cervical cancer (CEXF663)
Mean tumor volume +/- SEM (mm3)
2000
1500
1000
500
0
0
14
28
42
56
70
84
98
Days after tumor randomization
Isotype control IgG1 2mg/kg
Isotype control IgG1-MMAE 2mg/kg
Tisotumab vedotin 2mg/kg
Carboplatin 40mg/kg
Tisotumab vedotin 2mg/kg + carboplatin 40mg/kg
Treatment mAb
Treatment carboplatin

FIG. 4B


Cervical cancer (CEXF663)
Percent tumor free < 750mm3
100
50
0
0 10 20 30 40 50 60 70 80 90 100
Days after tumor randomization
Isotype control IgG1 2mg/kg
Isotype control IgG1-MMAE 2mg/kg
Tisotumab vedotin 2mg/kg
Carboplatin 40mg/kg
Tisotumab vedotin 2mg/kg + carboplatin 40mg/kg